Introduction {#sec1-1}
============

Breast Cancer (BCa) is a low-frequency neoplasm among young women; however, in the U.S., its prevalence has demonstrated an increase in women \<40 years of age (Ribnikar et al., 2015). In Mexico, BCa has become the most ubiquitous malignancy among female population and it has been established as a priority health issue (González-Robledo et al., 2013). On the other hand, prognosis of the neoplasm has been associated with multiple factors, such as clinical stage at diagnosis (Robles-Castillo et al., 2011; Cárdenas-Sánchez et al., 2015), age (Robles-Castillo et al., 2011; Cárdenas-Sánchez et al., 2015), hormonal phenotype, alterations in molecular mechanism (O'Connor et al., 2016), and metastasis (Bandala et al., 2015). The incidence of metastasis in BCa has shown considerable increases among women \<40 years of age, and it represents the main mortality factor in these women (Rodríguez-Cuevas et al., 2001; Ji et al., 2011). Some work has been conducted in order to find some methods that could predict the development of metastasis according to clinicopathological characteristics, but it has been limited (Anders et al., 2011; León-Hernández et al., 2014; Bandala et al., 2015; Swede et al., 2016). In this respect, the aim of the present work was to infer the clinicopathologic characteristics that could be related with the presence of metastasis in order to identify and control risk factors for BCa in younger Mexican women.

Materials and Methods {#sec1-2}
=====================

The files of patients with a diagnosis of BCa from 2010--2015 were 175, from which 20 cases involved women under the age of 40 years. The clinicopathologic data were analyzed according to ethic standards. The present work was approved by the local Ethical Research Committee, which granted approval with number 146.

Statistical analysis {#sec2-1}
--------------------

We performed descriptive statistics of the clinicopathological variables, applying the Kolmogorov--Smirnov test, the Student t test, the Chi square test, the Fisher test, and the Mantel-Haenzel analysis. The Odds Ratio (OR) was calculated for each variable in order to determine the putative risk or protective factors. All analyses were performed by SPSS ver. 19.0 statistical software, with a significance value of p \<0.05.

Results {#sec1-3}
=======

We found that highest prevalence of BCa occurred in 2010 in all ages, and interestingly, in 2012, the lowest global prevalence (all ages) and the lowest prevalence for women under the age of 40 years ([Figure 1](#F1){ref-type="fig"}) were reported. The year 2015, presented the highest frequency of patients with BCa of \<40 years of age (16.7%) related to all ages; their mean age was 36.4 ± 3.2 years, and minimal age was 30 years. According to risk factors, we found that this population presented a high frequency of obesity in \>75% of cases. In a similar manner, these women showed a high incidence of contraceptive consumption. Mean Body Mass Index (BMI) was 30.1 ± 5.2 kg/m^2^. According to the breast lesions, we could observe that there were no significance differences in terms of the affected breast (left or right): both breasts have the same probability of being affected. On the other hand and as expected the histological type with highest frequency, with 80% of the cases, was ductal carcinoma. The most frequent clinical stages were IIA and IV ([Figure 2](#F2){ref-type="fig"}). Immunohistochemical markers revealed that Ki67 were found in 91% of cases and, according to expectations, HER2 were present in only 13.3%. On the other hand, Estrogen Receptors (ER) were found in 61.1%. Subtype ER+/Progesterone Receptor (PR)+ was the most frequent subtype found, with 56.0%, followed by the baseline-like subtype with 33.3% ([Table 1](#T1){ref-type="table"}). Treatment frequencies were as follows: 85.0% chemotherapy; 55.6% radiotherapy, and 73.7% mastectomy. At diagnosis, a positive lymph node could be found in 47.1% of cases and the presence of metastasis in 35.3%; interestingly, we found that women \<40 years of age with smoking antecedents have a 5-times greater risk for metastasis and, more seriously, contraceptive consumption is associated with a 7-times greater risk for metastasis. On the other hand, there are apparently more probabilities for metastasis in ductal carcinoma when it appears in the right breast (p = 0.05) ([Table 2](#T2){ref-type="table"}). According to ImmunoHistoChemical (IHC) markers, we could observe that the absence of Progesterone Receptor (PR) is associated with high probabilities for metastasis. Interestingly, all patients (100.0%) with metastasis were negative for PR and, in addition, the absence of Estrogen Receptor (ER) confers a 12-times greater risk for metastasis; in the case of ER- and PR-, the risk for metastasis is 6-times higher, while, the presence of ER+, PR+, and absence of HER-2 is associated with a protective factor for developing metastasis ([Table 3](#T3){ref-type="table"}). Another important clue that we were able to observe was a significant association between metastasis and obesity (p \<0.05), this demonstrating that patients with obesity younger than the age of 40 years are most vulnerable to metastasis ([Figure 3](#F3){ref-type="fig"}). It is noteworthy that all cases with obesity and smoking presented metastasis, although only 16.7% of patients with obesity but who were non-smokers suffered from metastasis. As expected, clinical stage at diagnosis is important for preventing metastasis; these could be observed because patients diagnosed at clinical stage III or IV were more susceptible to metastasis (71.4%; p \<0.05). In the same manner, patients with infiltrating ductal carcinoma with stage III or IV at diagnosis showed metastasis in 100% of cases, but not another histological type. Type 2 Diabetes Mellitus (DM2) exhibited a interesting significance: we found that patients with DM2 and smoking antecedent demonstrated an increased risk for metastasis (p \<0.05); in the same respect, patients with DM2 diagnosed with stage III or IV possess greater susceptibility for metastasis (a 2.4-times greater risk; p \<0.05).
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###### 

Frequencies of Histopathologic Markers Determined in Women with Breast Cancer (BCa) Younger Than 40 Years of Age

  Markers   Frequency   Subtypes          Frequency
  --------- ----------- ----------------- -----------
  Her2      13.3%       (ER-/PR-)         31.3%
  PR+       50.0%       (ER+/PR+)         56.3%
  ER+       61.1%       (ER-/PR-/Her2-)   33.3%
  Ki67      91.7%       (ER+/PR+/Her2+)   6.3%

BCa, Breast Cancer; +, Positive marker; -, Negative marker; PR, Progesterone Receptor; ER, Estrogen Receptor

###### 

Metastasis Relationship to Lifestyle and Clinicopathological Risk Factors in Patients with Breast Cancer (BCa) Younger Than 40 Years of Age

                                  Metastasis                                                        
  ------------------------------- ------------ ------------ --------------------------------------- ----------------
  Smoking                         50% (3)      0            0.005[\*](#t2f1){ref-type="table-fn"}   5.3 (1.4-14.8)
  BMI (kg/m^2^)                   31.2 ± 5.2   29.2 ± 5.4   0.61                                    \-
  DM2                             16.7% (1)    7.7% (1)     0.54                                    2.4 (0.1-46.4)
  Early menarche                  50.0% (3)    23.0% (3)    0.39                                    2.3 (0.3-19.0)
  Nulliparity                     16.7% (1)    7.7% (1)     0.62                                    1.8 (0.1-35.4)
  Non- breastfeeding              16.7% (1)    7.7% (1)     0.65                                    1.6 (0.3-12.4)
  Oral contraceptive              83.3% (5)    30.8% (4)    0.04[\*](#t2f1){ref-type="table-fn"}    7.5 (0.01-1.6)
  Age at first pregnancy          17.0 ± 1.6   21.3 + 1.5   0.04[\*](#t2f1){ref-type="table-fn"}    \-
  Right breast                    83.3% (5)    38.5% (5)    0.0[\*](#t2f1){ref-type="table-fn"}     8.0 (0.7-90.0)
  Infiltrating ductal carcinoma   83.3% (5)    76.9% (10)   0.62                                    1.5 (0.1-18.4)
  Clinical stage III--IV          100.0% (6)   30.7% (4)    0.01[\*](#t2f1){ref-type="table-fn"}    \-

Statistical significance; BCa, Breast Cancer; BMI, Body Mass Index; DM2, Type 2 Diabetes Mellitus 2; OR, Odds Ratio; 95% CI, 95% Confidence Interval

###### 

Metastasis Relationship to Histopathologic Markers in Patients with Breast Cancer (BCa) Younger Than 40 Years of Age

                    Metastasis                                                      
  ----------------- ------------ ----------- -------------------------------------- ----------------------
  PR Negative       100.0% (4)   25.0% (3)   0.01[\*](#t3f1){ref-type="table-fn"}   \-
  ER Negative       75.0% (3)    25.0% (3)   0.03[\*](#t3f1){ref-type="table-fn"}   12 (0.006-1.09)
  Her2+             0.0          25.0% (3)   0.33                                   \-
  Ki67+             100.0% (4)   50.0% (6)   0.42                                   \-
  (ER-/PR-/Her2-)   75%(3)       16.6% (2)   0.05[\*](#t3f1){ref-type="table-fn"}   12 (0.77-86.36)
  (ER+/PR+/Her2+)   0.0          8.3% (1)    0.46                                   \-
  (ER-/PR-)         75.0% (3)    16.6% (2)   0.12                                   6 (0.56-63.98)
  (ER+/PR+)         25.0% (1)    66.6% (8)   0.05[\*](#t3f1){ref-type="table-fn"}   PF 9.33 (0.008-1.40)
  (ER+/PR+/Her2-)   25.0% (1)    50.0% (6)   0.42                                   PF 2.25 (0.05-3.97)

Statistical significance; PF, Protection Factor; +, Positive marker; -, Negative marker; PR, Progesterone Receptor; ER, Estrogen Receptor
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Discussion {#sec1-4}
==========

The incidence of BCa in young women is more frequent at the present time, and in Mexico, the incidence of these cases was reported as within a range of 10--15%. In our study, BCa global prevalence for women under the age of 40 years was 12%, similar to other studies performed in our country (Robles-Castillo et al., 2011; Villarreal-Garza et al., 2013), but were higher during 2015 (16.7%). It has been well reported that metastasis in young women is a frequent phenomenon, and in Mexico, it represents the 35--41% of these types of patients (Villarreal-Garza et al., 2013; León-Hernández et al., 2014). In this study, we reported obesity in nearly 66% of the cases analyzed, and previously, some reports revealed that obesity could be a protective factor in young women (Anders et al., 2009; Connor et al., 2013; Bandala et al., 2015). However, but in our case, we found a potential positive association between metastasis and obesity, similar to other reports (Chen et al., 2016). It is reported that the most frequent histological type in women younger than 40 years of age is ductal infiltrating carcinoma, representing in the U.S. 74.3%, in Europe 85%, and in Mexico, 88--96% (Kheirelseid et al., 2011; Robles-Castillo et al., 2011; Copson et al., 2013; Villarreal-Garza et al., 2013; Bandala et al., 2015). According to the literature, we found this histological type in 80% of cases and, similar to other reports, we observed that these lesions are associated with a high risk for metastasis (Johnson et al., 2013; Copson et al., 2013): however, we are not able to discard some variation related with geographical distribution or the patients' ethnic backgrounds (Smigal et al., 2006; Sachdev et al. 2010; Starlard et al., 2013). On the other hand, some studies reported that young women have high probabilities of being diagnosed at advanced stages (Kheirelseid et al., 2011; Robles-Castillo et al., 2011; Bandala et al., 2012; Copson et al., 2013; Villarreal-Garza et al., 2013). In this case, we found a high percentage of women with stages III or IV (26.31 and 26.32%, respectively), representing one half of the analyzed patients; this could be explained as due to that the female population presented for breast medical examination after the age of 40 years or when they found an atypical breast formation, in other words, when the tumor was advanced (Rodríguez-Cuevas et al., 2000).

According to IHC markers, we found the presence of hormonal receptors (ER or PR) in one half of the samples, followed by baseline-like phenotype in approximately 30% of cases. In this regard, it is well known that the presence of both hormonal receptors with a negative expression of HER2 is a good prognosis marker (Puig-Vives et al., 2013), and in this study, we found a protective factor of 9.33 times in this phenotype, similar to others reports (Kheirelseid et al., 2011; Liukkonen et al., 2011; Copson et al., 2013). Meanwhile, subtype luminal-B HER2-positive, HER2-positive, and baseline-like phenotypes have been associated with poor prognosis, and in this study, we found similar data: in this case, these phenotypes confer a 12-times greater risk for developing metastasis, and this probably could be the reason for poor prognosis in these IHC markers (Johnson et al., 2013; Puig-Vives et al., 2013; Aktas et al., 2016). Many authors have studied smoking as a risk factor in BCa, showing that cigarette smoking is associated with a short survival time after treatment (Stefani et al., 2011; Park et al., 2012; Gou et al., 2013; Persson et al., 2016); in this study, we showed that the risk for metastasis is higher in patients with a history of smoking, and this could be explained in part by an adaptative mechanism of tumor cells produced by chromosomal imbalance or toxicity due to cigarette consumption (Hyndman 2016). On the other hand, in the present study, we found an association between DM2 and metastasis; these results are similar to those of other works, indicating that this has been associated with poor prognosis and perhaps with metastasis, due to that insulin resistance promotes tumor cell growth, and increases Reactive Oxygen Species (ROS) and the production of pro-angiogenic cytokines (Sciacca et al., 2013; Ferroni et al., 2015; O'Connor et al., 2016).

In this study, we provide some interesting data on the increase of the risk of metastasis according to some variables that could be useful in predicting disease evolution and treatment response; in this case, we could conclude that knowledge about risk factors or protective factors in BCa supply a very important clue, which could be applied in clinical practice in order to furnish a close vision of patient prognosis and to reduce institutional costs for failed or incorrect treatments.
